Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
Christie M. Ballantyne, Ulrich Laufs, Kausik K. Ray, et al.
European Journal of Preventive Cardiology (2019) Vol. 27, Iss. 6, pp. 593-603
Open Access | Times Cited: 297

Showing 1-25 of 297 citing articles:

2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, et al.
European Heart Journal (2024) Vol. 45, Iss. 36, pp. 3415-3537
Open Access | Times Cited: 525
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd‐Jones, Pamela B. Morris, Christie M. Ballantyne, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 14, pp. 1366-1418
Open Access | Times Cited: 305
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics
Yajun Duan, Ke Gong, Suowen Xu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 249
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary
Yehuda Handelsman, Paul S. Jellinger, Chris Guerin, et al.
Endocrine Practice (2020) Vol. 26, Iss. 10, pp. 1196-1224
Closed Access | Times Cited: 203
Ten things to know about ten cardiovascular disease risk factors
Harold Bays, Pam R. Taub, Elizabeth Epstein, et al.
American Journal of Preventive Cardiology (2021) Vol. 5, pp. 100149-100149
Open Access | Times Cited: 176
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Maciej Banach, P. Barton Duell, Antonio M. Gotto, et al.
JAMA Cardiology (2020) Vol. 5, Iss. 10, pp. 1124-1124
Open Access | Times Cited: 165
Multifunctional nanoparticle-mediated combining therapy for human diseases
Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 140
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, et al.
Archives of Medical Science (2021) Vol. 17, Iss. 6, pp. 1447-1547
Open Access | Times Cited: 133
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
Maurizio Averna, Maciej Banach, Éric Bruckert, et al.
Atherosclerosis (2021) Vol. 325, pp. 99-109
Closed Access | Times Cited: 118
Role of Bempedoic Acid in Clinical Practice
Christie M. Ballantyne, Harold Bays, Alberico L. Catapano, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 35, Iss. 4, pp. 853-864
Open Access | Times Cited: 114
The dawn of a new era of targeted lipid-lowering therapies
Lâle Tokgözoğlu, Peter Libby
European Heart Journal (2021) Vol. 43, Iss. 34, pp. 3198-3208
Open Access | Times Cited: 111
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient
Mary Katherine Cheeley, Joseph J. Saseen, Anandita Agarwala, et al.
Journal of clinical lipidology (2022) Vol. 16, Iss. 4, pp. 361-375
Open Access | Times Cited: 106
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 84
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Kausik K. Ray, Stephen J. Nicholls, Na Li, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 12, Iss. 1, pp. 19-28
Open Access | Times Cited: 51
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Sunil V. Rao, Michelle L. O’Donoghue, Marc Ruel, et al.
Circulation (2025)
Closed Access | Times Cited: 24
American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia
Shailendra B. Patel, Kathleen Wyne, Samina Afreen, et al.
Endocrine Practice (2025) Vol. 31, Iss. 2, pp. 236-262
Closed Access | Times Cited: 5
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Sunil V. Rao, Michelle L. O’Donoghue, Marc Ruel, et al.
Journal of the American College of Cardiology (2025)
Closed Access | Times Cited: 4
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
StephenJ Nicholls, A. Michael Lincoff, Harold Bays, et al.
American Heart Journal (2020) Vol. 235, pp. 104-112
Closed Access | Times Cited: 121
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
Arrigo F.G. Cicero, Federica Fogacci, Adrían V. Hernández, et al.
PLoS Medicine (2020) Vol. 17, Iss. 7, pp. e1003121-e1003121
Open Access | Times Cited: 84
Emerging views of statin pleiotropy and cholesterol lowering
Dongbo Yu, James K. Liao
Cardiovascular Research (2021) Vol. 118, Iss. 2, pp. 413-423
Open Access | Times Cited: 82
Bempedoic Acid: First Approval
Anthony Markham
Drugs (2020) Vol. 80, Iss. 7, pp. 747-753
Closed Access | Times Cited: 80
Clinical approach to the inflammatory etiology of cardiovascular diseases
Massimiliano Ruscica, Alberto Corsini, Nicola Ferri, et al.
Pharmacological Research (2020) Vol. 159, pp. 104916-104916
Open Access | Times Cited: 76
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nick S. Nurmohamed, Ann Marie Návar, John J.P. Kastelein
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 12, pp. 1564-1575
Open Access | Times Cited: 70
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Maciej Banach, Stanisław Surma, Željko Reiner, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 68
New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
Dan Atar, J. Wouter Jukema, Bart Molemans, et al.
Atherosclerosis (2021) Vol. 319, pp. 51-61
Open Access | Times Cited: 66
Page 1 - Next Page

Scroll to top